NEW YORK (GenomeWeb) – Biocartis said today that it is collaborating with medical research charity MRC Technology to develop molecular diagnostic tests for use on the Biocartis fully automated Idylla platform.

Under the terms of the agreement, MRCT will act as a development contractor and Biocartis will be responsible for the commercialization of the tests under its own label. Financial details of the partnership were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.